Erythromelalgia in Essential Thrombocythemia Is Characterized by Platelet Activation and Endothelial Cell Damage but not by Thrombin Generation

Summary

Erythromelalgia, a characteristic aspirin-responsive microvascular thrombotic complication in essential thrombocythemia (ET), may develop despite oral anticoagulant treatment or treatment with heparin, suggesting that the generation of thrombin is not a prerequisite for its development. To study this, a cross-sectional comparison of the plasma levels of thrombomodulin (TM), platelet factor 4 (PF4), β-thrombo-globulin (β-TG), prothrombin fragment 1+2 (F1+2) and total degradation products of fibrin(ogen) (TDP) was made between 5 ET patients suffering from erythromelalgia, 16 asymptomatic ET patients and 20 control subjects, and after treatment with aspirin, respectively. Furthermore, 2 ET patients with a history of erythromelalgia were studied at regular time intervals after discontinuation of aspirin until erythromelalgia recurred. As compared with asymptomatic ET patients and control subjects erythromelalgia was characterized by significantly higher β-TG and TM levels but no significant differences were detected in either F1+2 or TDP levels. Treatment of erythromelalgia with aspirin resulted in disappearance of erythromelalgic signs and symptoms, which was paralleled by a significant decrease of β-TG and TM levels. Histopathologic and immunohistochemical analysis of biopsies derived from erythromelalgic skin areas of 2ET patients showed that erythromelalgic thrombi stained positively for von Wille-brand factor opposed to only a weak fibrin staining. Our data suggest that erythromelalgia is caused by the intravascular activation and aggregation of platelets with subsequent sludging or occlusion of the acral arterial microvasculature. The generation of thrombin appears not to be essential for the formation of these platelet thrombi, thereby giving a plausible explanantion for the inefficacy of coumadin derivatives and heparin in the prevention and treatment of erythromelalgia in essential thrombocythemia.

• References

• 1 Michiels JJ, Abels J, Steketee J, van Vliet HHDM, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 1985; 102: 466-471
• 2 van Genderen PJJ, Michiels JJ. Primary thrombocythemia: diagnosis, clinical manifestations and management. Ann Hematole 1993; 67: 57-62
• 3 Michiels JJ, van Joost Th. Erythromelalgia and thrombocythemia: a causal relation. Am J Acad Dermatol 1990; 22: 107-111
• 4 Michiels JJ, Ten Kate FWJ, Vuzevski VD, Abels J. Histopathology of erythromelalgia in thrombocythemia. Histopathology 1984; 8: 669-678
• 5 van Genderen PJJ, Michiels JJ, van Strik R, Lindemans J, van Vliet HHDM. Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb Haemost 1995; 73: 210-214
• 6 Vreeken J, van Aken WG. Spontaneous aggregation of blood platelets as a cause of idiopathic thrombosis and recurrent painful toes and fingers. Lancet 1971; ii: 1394-1397
• 7 Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Sem Hematol 1986; 23: 177-182
• 8 Rocca B, Ciabattoni G, Tartaglione R, Cortelazzo S, Barbui T, Patrono C, Landolfi R. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 1995; 74: 1225-1230
• 9 Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-1372
• 10 Cortelazzo S, Viero P, Barbui T. Platelet activation in myeloproliferative disorders. Thromb Haemost 1981; 45: 211-213
• 11 Lendrum AC, Fraser DS, Slidders W, Henderson R. Studies on the character and staining of fibrin. J Clin Path 1962; 15: 401-413
• 12 Bellucci S, Ignatova E, Jaillet N, Boffa MC. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF. Thromb Haemost 1993; 70: 736-742
• 13 Wada H, Ohiwa M, Kaneko T, Tamaki S, Tanigawa M, Shirakawa S, Koyama M, Hayashi T, Suzuki K. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol 1992; 3: 20-24
• 14 Karmochkine M, Boffa MC, Piette JC, Cacoub P, Wechsler B, Godeau P, Juhan I, Weiller PJ. Increase in plasma thrombomodulin in lupus erythematosus with antiphospholipid antibodies. Blood 1992; 79: 837-838
• 15 Tanaka A, Ishii H, Hiraishi S, Kazama M, Mazewa H. Increased thrombomodulin values in plasma of diabetic men with microangiopathy. Clin Chem 1991; 37: 269-272
• 16 Tani N, Hada K, Kitami A, Nakano M, Takahashi H, Ito S, Sato I, Shibata A. Effects of acetyl salicylic acid and cilostazol administration on serum thrombomodulin concentration in diabetic patients. Thromb Res 1993; 69: 153-158
• 17 Szczeklik A, Krzanowski M, Gora P, Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood 1992; 80: 2006-2011
• 18 Kessels H, Beguin S, Andree H, Hemker HC. Measurement of thrombin generation in whole blood - the effect of heparin and aspirin. Thromb Haemost 1994; 72: 78-83
• 19 Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immuno-histochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985; 38: 469-479
• 20 Moake JL. Haemolytic-uraemic syndrome: basic science. Lancet 1994; 343: 393-397
• 21 Yosipovitch Y, Ilan Krause, Blickstein D. Erythromelalgia in a patient with thrombotic thrombocytopenic purpura. J Am Acad Dermatol 1992; 26: 825-827